Skip to main content
. Author manuscript; available in PMC: 2022 Jun 14.
Published in final edited form as: Lancet. 2021 Jan 16;397(10270):208–219. doi: 10.1016/S0140-6736(20)32514-9

Table 1.

Baseline Characteristics

Overall N=113 Age 14–20 N=73 Age 21–29 N=40

Age – Mean ± SD years 19 ± 4 17 ± 2 24 ± 3
Median Duration of Diabetes (IQR) - years 12 (7, 15) 10 (6, 13) 15 (13, 18)
Insulin Delivery N (%)
 Insulin Pump 90 (80%) 59 (81%) 31 (78%)
 Multiple Daily Injections 23 (20%) 14 (19%) 9 (23%)
Use of a Continuous Glucose Monitor at Enrollment – N (%) 70 (62%) 47 (64%) 23 (58%)
Use of MiniMed 670G in Auto Mode at Enrollment – N (%) 15 (13%) 8 (11%) 7 (18%)
Body Mass Index – median (IQR)
 Participants ≥18 years old kg/m2 26 (23, 29)
 Participants <18 years old percentile 81% (56%,90%)
Female Sex – N (%) 70 (62%) 42 (58%) 28 (70%)
Race – N (%)
 White 104 (92%) 68 (93%) 36 (90%)
 Black/African American 3 (3%) 1 (1%) 2 (5%)
 Hispanic or Latino 5 (4%) 3 (4%) 2 (5%)
 More than One Race 1 (<1%) 1 (1%) 0 (0%)
Highest Education Levela
 ≤ H.S. diploma 20 (18%) 16 (22%) 4 (10%)
 Associates Degree/Some College but no Degree 40 (35%) 22 (30%) 18 (45%)
 Bachelor’s Degree 34 (30%) 20 (27%) 14 (35%)
 Master’s Degree 12 (11%) 9 (12%) 3 (8%)
 Doctoral or Prof Degree 7 (6%) 6 (8%) 1 (3%)
HbA1c at Screening – N (%)
 ≤8·5% (≤69 mmol/mol) 83 (73%) 51 (70%) 32 (80%)
 ≥8·6% (≥70 mmol/mol) 30 (27%) 22 (30%) 8 (20%)
mean ± SD % (mmol/mol) 8·1 ± 0·8 (65±9) 8·2 ± 0·8 (66±9) 7·9 ± 0·7 (63±8)
HbA1c at Randomization – N (%)
 ≤8·5% (≤69 mmol/mol) 97 (86%) 60 (82%) 37 (93%)
 ≥8·6% (≥70 mmol/mol) 16 (14%) 13 (18%) 3 (8%)
mean ± SD % (mmol/mol) 7·9 ± 0·7 (63±8) 8·0 ± 0·7 (64±8) 7·7 ± 0·6 (61±6)
a

Highest level completed by participant, or by primary caregiver if participant <18 years old.

HHS Vulnerability Disclosure